Marshall Wace’s SeaStar Medical ICU Stock Holding History

Marshall Wace’s Portfolio ICU Stock Details ICU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-156	Closed	-$401K	–	3153
2022 Q3	$401K	Hold	156	–	–	﹤0.01%	2824
2022 Q2	$397K	Hold	156	–	–	﹤0.01%	2908
2022 Q1	$396K	Hold	156	–	–	﹤0.01%	2872
2021 Q4	$392K	Buy	+156	New	+$390K	﹤0.01%	2922

Other funds holding ICU

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CCFM

Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return

SWA

SFMG Wealth Advisors Plano, Texas $1.48B AUM 15.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's ICU Position: Q4 2022 in Review

Marshall Wace sold out of SeaStar Medical (ICU) in Q4 2022, closing a stake of 156 shares — an estimated $401K sold.

Marshall Wace first reported a position in ICU in Q4 2021 and held it in 4 quarters. The position peaked at $401K in Q3 2022. 8 funds tracked by Wall St. Rank hold ICU as of Q4 2022.

Marshall Wace reported no remaining SeaStar Medical position as of Q4 2022 after selling out during the quarter.
Marshall Wace sold 156 SeaStar Medical shares in Q4 2022, an estimated $401K.
Marshall Wace first reported a position in SeaStar Medical in Q4 2021 and held it in 4 quarters.
Marshall Wace's SeaStar Medical position peaked at $401K in Q3 2022.
8 funds tracked by Wall St. Rank held SeaStar Medical as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.